Clinical Trial: A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease

U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT06984627) titled 'A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease' on May 14.

Brief Summary: This is a parallel group, Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves' disease, with and without Graves' orbitopathy, aged 18 years or older.

Study details include:

* Screening period (up to 4 weeks).

* Treatment period (up to 16 weeks).

* Follow-up period (4 weeks). The number of visits will be up to 13.

Study Start Date: May 30

Study Type: INTERVENTIONAL

Condition: Graves' Disease

Intervention: D...